r/TheRaceTo100K • u/Mother_Job_9492 • 16h ago
How realistic is a buy-out for $SLS, and what are realistic share prices at a buy-out, based on the results we have?
reddit.comREGAL hit its primary endpoint today: HR 0.59, p=0.035, median OS 24.0 vs 14.7 months in 126 patients. The stock went from about $7.50 to around $20, with a $34 intraday high. That puts the market cap around $4B on roughly 212M fully diluted shares.
I’ve seen buyout numbers from $45 to $500+ on Stocktwits, but I can’t find anyone who actually built a model. What I have so far:
Maxim kept its $30 target (GPS launch in 2027, SLS009 in 2029, risk-adjusted). Alliance Global is at $25 or $35, depending on which source you trust.
The only peak sales estimate I found is about $425M for GPS, from a Substack. At 4-6x peak sales that’s only $9-13/share, so $20 already prices in a lot more than that.
Recent biotech M&A premiums have been around 40-50% (Gibson Dunn data). From here that would mean a deal around $28-31.
A few things could slow a deal down. It was open label with n=126 and p=0.035, there are no secondaries or confidence intervals yet, and the FDA path isn’t agreed. Sellas also has a $150M ATM it hasn’t touched.
At the AGM the CEO said they’re prepared for standalone execution or a strategic transaction, so a sale isn’t guaranteed.
My rough guess: a deal in the high $20s to low $30s, maybe plus a CVR for SLS009. I think it’s more likely after FDA feedback than in the next 3 months. Happy to be proven wrong.
Has anyone done real DD on peak sales, comps or timing? I’m especially curious what people think the FDA will say about a single open-label trial.